UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-35625 BLOOMIN' BRANDS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Exhibit 99.1 Teknova Reports Second Quarter 2025 Financial Results Matt Lowell, Teknova's Chief Financial Officer, added, "Compared to 2024, we delivered 7% revenue growth in the second quarter 2025 along with significant improvements in adjusted EBITDA and free cash outflow. We believe the Company is well positioned to maintain its momentum. We therefore reiterate our 2025 revenue guidance of $39-42 million and continue to anticipate full-year free cash outflow of less than $12 million," he explained. Corp ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company's financial statements show increased assets, continued net losses, and sufficient liquidity, primarily from equity offerings Condensed Consolidated Balance Sheet Data (in thousands) | Balance Sheet Items | June 30, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $17,220 | $11,055 | | Total current assets | $87,492 | $81,954 | | **Total assets** | **$101,534** | **$96,830** | | Total current liabilities | $15,531 | $14,967 | | **Total liabilities** | **$26,878** | **$26,998** | | **Total stockholders' equity** | **$74,656** | **$69,832** | | Accumulated deficit | ($566,457) | ($532,046) | Condensed Consolidated Statements of Operations Data (in thousands, except per share data) | Income Statement Items | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $— | $— | $— | $235 | | Research and development | $15,384 | $13,973 | $27,198 | $27,337 | | General and administrative | $4,929 | $3,342 | $8,888 | $6,849 | | **Loss from operations** | **($20,313)** | **($17,315)** | **($36,086)** | **($33,951)** | | **Net loss attributable to aTyr** | **($19,531)** | **($16,306)** | **($34,411)** | **($31,797)** | | Net loss per share, basic and diluted | ($0.22) | ($0.23) | ($0.39) | ($0.46) | Condensed Consolidated Statements of Cash Flows Data (in thousands) | Cash Flow Items | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($29,314) | ($42,829) | | Net cash (used in) provided by investing activities | ($1,119) | $5,372 | | Net cash provided by financing activities | $36,525 | $21,130 | | **Net change in cash, cash equivalents and restricted cash** | **$6,092** | **($16,327)** | - The company has incurred net losses since its inception in 2005, with an accumulated deficit of **$566.5 million** as of June 30, 2025[26](index=26&type=chunk) - Management believes that existing cash, cash equivalents, restricted cash, and available-for-sale investments of **$83.2 million** as of June 30, 2025, will be sufficient to meet material cash requirements for at least one year from the filing date of this report[28](index=28&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage pipeline, financial performance, and funding strategies, with key updates on efzofitimod [Overview](index=22&type=section&id=Overview) aTyr Pharma is a clinical-stage biotech advancing efzofitimod for ILD, with Phase 3 data expected soon, and other preclinical candidates - The lead therapeutic candidate is **efzofitimod**, a first-in-class biologic immunomodulator for treating interstitial lung disease (ILD)[70](index=70&type=chunk) - The global pivotal Phase 3 EFZO-FIT study for pulmonary sarcoidosis completed enrollment of 268 subjects in July 2024 and the last patient visit was completed in July 2025, with topline data expected in **mid-September 2025**[74](index=74&type=chunk) - The Phase 2 EFZO-CONNECT study in patients with SSc-ILD is ongoing, with interim data in June 2025 showing clinically important improvement in skin scores for **three of four** efzofitimod-treated patients[76](index=76&type=chunk) - The collaboration with Kyorin for efzofitimod in Japan has generated **$20.0 million** in payments to date, with up to an additional **$155.0 million** in potential milestones, plus royalties[77](index=77&type=chunk) [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity, accumulated deficit, and funding sources are discussed, highlighting reliance on equity offerings and changes in cash flow from operations - As of June 30, 2025, the company had cash, cash equivalents, restricted cash, and available-for-sale investments of **$83.2 million** and an accumulated deficit of **$566.5 million**[82](index=82&type=chunk) - The company sold **8,771,725 shares** of common stock for net proceeds of approximately **$36.7 million** under its ATM Offering Program during the six months ended June 30, 2025[85](index=85&type=chunk) Summary of Net Cash Flow (in thousands) | Period | Net Cash Used in Operating Activities | Net Cash (Used in)/Provided by Investing Activities | Net Cash Provided by Financing Activities | | :--- | :--- | :--- | :--- | | **Six Months Ended June 30, 2025** | $(29,314) | $(1,119) | $36,525 | | **Six Months Ended June 30, 2024** | $(42,829) | $5,372 | $21,130 | - The decrease in net cash used in operating activities in H1 2025 compared to H1 2024 was primarily due to the timing of certain upfront efzofitimod manufacturing payments made in 2024[87](index=87&type=chunk) [Results of Operations](index=34&type=section&id=Results%20of%20Operations) Operating expenses increased in Q2 2025 due to higher R&D and G&A costs, with similar trends for the first six months, and further increases are anticipated Comparison of Operating Expenses for the Three Months Ended June 30 (in thousands) | Expense Category | 2025 | 2024 | Increase / (Decrease) | | :--- | :--- | :--- | :--- | | **Total research and development expenses** | **$15,384** | **$13,973** | **$1,411** | | **Total general and administrative expenses** | **$4,929** | **$3,342** | **$1,587** | - The **$1.4 million** increase in Q2 2025 R&D expenses was primarily due to a **$1.0 million** increase in manufacturing costs for a potential BLA filing for efzofitimod[107](index=107&type=chunk) - The **$1.6 million** increase in Q2 2025 G&A expenses was mainly due to a **$1.2 million** increase in personnel and pre-commercialization costs[108](index=108&type=chunk) Comparison of Operating Expenses for the Six Months Ended June 30 (in thousands) | Expense Category | 2025 | 2024 | Increase / (Decrease) | | :--- | :--- | :--- | :--- | | **Total research and development expenses** | **$27,198** | **$27,337** | **($139)** | | **Total general and administrative expenses** | **$8,888** | **$6,849** | **$2,039** | [Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that this item is not applicable - Not applicable[116](index=116&type=chunk) [Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of the end of the quarter, with no material changes identified - Based on an evaluation as of the end of the quarter, the Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level[118](index=118&type=chunk) - No changes in internal control over financial reporting were identified during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[119](index=119&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings, though it may face routine claims in the ordinary course of business - aTyr Pharma is not a party to any material legal proceedings at this time[121](index=121&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks related to clinical trial success, manufacturing, capital requirements, third-party collaborations, and market volatility - The company may face substantial delays in clinical trials and may fail to demonstrate safety and efficacy, particularly for the EFZO-FIT study, as there is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis[123](index=123&type=chunk)[133](index=133&type=chunk) - The company faces risks of manufacturing stoppages and challenges with its CDMOs, which could affect the clinical or commercial manufacture of its product candidates and regulatory activities required for a BLA submission[123](index=123&type=chunk)[146](index=146&type=chunk) - The company has a history of significant losses and will need to raise additional capital to fund operations, which may not be available on favorable terms or at all[123](index=123&type=chunk)[179](index=179&type=chunk) - The company depends on its collaboration with Kyorin for the development and commercialization of efzofitimod in Japan, and if this collaboration is not successful, the market potential may not be realized[126](index=126&type=chunk)[191](index=191&type=chunk) - The market price of the company's common stock has been and is likely to continue to be highly volatile[126](index=126&type=chunk)[295](index=295&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=105&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[345](index=345&type=chunk) [Defaults Upon Senior Securities](index=105&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[346](index=346&type=chunk) [Mine Safety Disclosures](index=105&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[347](index=347&type=chunk) [Other Information](index=105&type=section&id=Item%205.%20Other%20Information) During the quarter, the Chief Financial Officer and General Counsel adopted Rule 10b5-1 trading plans for pre-arranged security sales Executive Trading Arrangements (Rule 10b5-1) | Name and Title | Action | Adoption Date | Total Shares to be Sold (Max) | Expiration Date | | :--- | :--- | :--- | :--- | :--- | | Jill M. Broadfoot, Chief Financial Officer | Adoption | 6/16/2025 | 252,514 | 6/16/2026 | | Nancy E. Denyes, General Counsel | Adoption | 6/13/2025 | 100,000 | 6/13/2026 | [Exhibits](index=106&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Quarterly Report on Form 10-Q, including corporate governance and certification documents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

IRVINE, Calif., August 7, 2025 – Xponential Fitness, Inc. (NYSE: XPOF) ("Xponential" or the "Company"), one of the leading global franchisors of boutique health and wellness brands, today reported financial results for the second quarter ended June 30, 2025. All financial data included in this release refer to global numbers, unless otherwise noted. All KPI information is presented on an adjusted basis to include full historical data for all brands in the brand portfolio as of June 30, 2025, and to exclude ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ GENELUX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 001-41599 77-0583529 Commissio ...

[Second Quarter 2025 Financial Results](index=1&type=section&id=AKAMAI%20REPORTS%20SECOND%20QUARTER%202025%20FINANCIAL%20RESULTS) This section details Akamai's strong Q2 2025 financial performance, exceeding expectations and leading to raised full-year guidance [Performance Summary](index=1&type=section&id=Performance%20Summary) Akamai reported strong Q2 2025 results, exceeding revenue and profitability expectations. Total revenue grew 7% year-over-year to $1.043 billion, driven by significant growth in Security (+11%) and Cloud Computing (+13%), particularly Cloud Infrastructure Services which surged 30%. This performance led the company to raise its full-year guidance for both revenue and earnings. Non-GAAP net income per diluted share increased by 9% to $1.73 Q2 2025 Key Financial Highlights (YoY) | Metric | Q2 2025 | Growth (YoY) | Growth (YoY, Constant Currency) | | :--- | :--- | :--- | :--- | | **Total Revenue** | $1.043 billion | 7% | 6% | | **Cloud Infrastructure Services Revenue** | $71 million | 30% | 29% | | **GAAP Net Income per Diluted Share** | $0.71 | -17% | -18% | | **Non-GAAP Net Income per Diluted Share** | $1.73 | 9% | 9% | - CEO Tom Leighton highlighted strong momentum, leading to increased full-year guidance. He emphasized that investments in security and cloud computing are paying off and sees AI as a strong tailwind for the business[2](index=2&type=chunk) Q2 2025 Revenue Breakdown (YoY, Constant Currency) | Revenue by Solution | Amount | Growth (YoY, CC) | | :--- | :--- | :--- | | Security | $552 million | 10% | | Delivery | $320 million | -4% | | Cloud Computing | $171 million | 13% | | **Revenue by Geography** | **Amount** | **Growth (YoY, CC)** | | U.S. | $528 million | 4% | | International | $516 million | 8% | - The company executed **$300 million** in share repurchases during the quarter, buying back **3.9 million shares** at an average price of **$77.51**[6](index=6&type=chunk) [Financial Guidance](index=2&type=section&id=Financial%20guidance) Akamai has raised its financial outlook for the remainder of the year. For the third quarter of 2025, the company projects revenue between $1.035 billion and $1.050 billion, with non-GAAP EPS of $1.62 to $1.66. For the full year 2025, revenue is now expected to be in the range of $4.135 billion to $4.205 billion, with non-GAAP EPS between $6.60 and $6.80 Q3 and Full Year 2025 Financial Guidance | Guidance Metric | Q3 2025 | Full Year 2025 | | :--- | :--- | :--- | | **Revenue** | $1,035M - $1,050M | $4,135M - $4,205M | | **Non-GAAP Operating Margin** | 28% | 29% | | **Non-GAAP EPS** | $1.62 - $1.66 | $6.60 - $6.80 | [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents Akamai's condensed consolidated balance sheets, income statements, and cash flow statements [Condensed Consolidated Balance Sheets](index=4&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, Akamai's balance sheet shows total assets of $10.54 billion, a slight increase from $10.37 billion at year-end 2024. Key changes include a decrease in marketable securities and a significant increase in convertible senior notes, reflecting financing activities during the period. Total stockholders' equity decreased from $4.88 billion to $4.47 billion Balance Sheet Summary (as of June 30, 2025) | Account | June 30, 2025 (in thousands) | Dec 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $2,033,827 | $2,578,097 | | **Total Assets** | $10,536,135 | $10,368,785 | | **Total Current Liabilities** | $880,519 | $2,091,323 | | **Convertible senior notes (non-current)** | $4,100,977 | $2,396,695 | | **Total Liabilities** | $6,068,627 | $5,490,428 | | **Total Stockholders' Equity** | $4,467,508 | $4,878,357 | [Condensed Consolidated Statements of Income](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20INCOME) For the three months ended June 30, 2025, Akamai generated revenue of $1.043 billion, up from $980 million in the prior year period. However, due to higher operating expenses and a larger provision for income taxes, GAAP net income decreased to $104 million from $132 million year-over-year, resulting in a GAAP diluted EPS of $0.71 compared to $0.86 Income Statement Highlights (Three Months Ended June 30) | Metric (in thousands) | 2025 | 2024 | | :--- | :--- | :--- | | **Revenue** | $1,043,494 | $979,580 | | **Income from Operations** | $151,461 | $147,986 | | **Net Income** | $103,618 | $131,688 | | **Diluted EPS** | $0.71 | $0.86 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) In the second quarter of 2025, Akamai generated strong net cash from operating activities of $459 million. Investing activities resulted in a net cash outflow of $683 million, primarily due to purchases of property, equipment, and marketable securities. Financing activities showed a net cash outflow of $41 million, driven by $300 million in common stock repurchases, offset by proceeds from the issuance of new convertible senior notes and related transactions Cash Flow Summary (Three Months Ended June 30, 2025) | Activity (in thousands) | Q2 2025 | | :--- | :--- | | **Net cash provided by operating activities** | $459,149 | | **Net cash used in investing activities** | ($682,866) | | **Net cash used in financing activities** | ($41,205) | [Supplemental Financial Data](index=8&type=section&id=Supplemental%20Financial%20Data) This section provides additional detailed breakdowns of revenue by solution and geography, along with other key operational metrics [Revenue by Solution](index=8&type=section&id=SUPPLEMENTAL%20REVENUE%20DATA%20%E2%80%93%20REVENUE%20BY%20SOLUTION) In Q2 2025, Security revenue grew 11% year-over-year to $552 million, and Cloud Computing revenue increased 13% to $171 million. Conversely, Delivery revenue continued its decline, falling 3% to $320 million. On a constant currency basis, Security grew 10% while Delivery declined 4% Q2 2025 Revenue by Solution (YoY Growth) | Solution | Revenue (in thousands) | YoY Growth | YoY Growth (Constant Currency) | | :--- | :--- | :--- | :--- | | **Security** | $551,914 | 11% | 10% | | **Delivery** | $320,125 | -3% | -4% | | **Cloud computing** | $171,455 | 13% | 13% | [Revenue by Geography](index=8&type=section&id=SUPPLEMENTAL%20REVENUE%20DATA%20%E2%80%93%20REVENUE%20BY%20GEOGRAPHY) Geographically, International revenue growth outpaced U.S. growth in Q2 2025. International revenue grew 10% year-over-year (8% in constant currency) to $516 million, while U.S. revenue grew 4% to $528 million Q2 2025 Revenue by Geography (YoY Growth) | Geography | Revenue (in thousands) | YoY Growth | YoY Growth (Constant Currency) | | :--- | :--- | :--- | :--- | | **U.S.** | $527,607 | 4% | 4% | | **International** | $515,887 | 10% | 8% | [Other Supplemental Data](index=9&type=section&id=OTHER%20SUPPLEMENTAL%20DATA) This section provides detailed breakdowns of key operational and financial metrics. For Q2 2025, total stock-based compensation was $112.8 million. Total capital expenditures on an accrual basis were $214.2 million, representing 21% of revenue for the quarter. The company's employee count stood at 10,944 at the end of the period - Total stock-based compensation for Q2 2025 was **$112.8 million**, an increase from **$98.5 million** in Q2 2024[17](index=17&type=chunk) - Total capital expenditures (accrual basis) were **$214.2 million** in Q2 2025, equivalent to **21% of revenue**, up from **17% of revenue** in the prior year quarter[17](index=17&type=chunk) [Reconciliation of GAAP to Non-GAAP Measures](index=10&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) This section reconciles GAAP financial results to non-GAAP measures for income from operations, net income, and diluted earnings per share [Reconciliation of Income from Operations and Net Income](index=10&type=section&id=RECONCILIATION%20OF%20GAAP%20TO%20NON-GAAP%20INCOME%20FROM%20OPERATIONS%2C%20NET%20INCOME%20AND%20TAX%20RATE) For Q2 2025, Akamai's GAAP income from operations was $151.5 million. After adjusting for items such as stock-based compensation ($112.8 million) and amortization of acquired intangible assets ($27.7 million), the non-GAAP income from operations was $308.6 million. Similarly, GAAP net income of $103.6 million was reconciled to a non-GAAP net income of $251.4 million Q2 2025 GAAP to Non-GAAP Reconciliation (in thousands) | Metric | GAAP | Key Adjustments | Non-GAAP | | :--- | :--- | :--- | :--- | | **Income from Operations** | $151,461 | +$157,162 | $308,623 | | **Operating Margin** | 15% | | 30% | | **Net Income** | $103,618 | +$147,738 | $251,356 | [Reconciliation of Net Income per Diluted Share](index=11&type=section&id=RECONCILIATION%20OF%20GAAP%20TO%20NON-GAAP%20NET%20INCOME%20PER%20DILUTED%20SHARE) The company's GAAP net income per diluted share of $0.71 for Q2 2025 is reconciled to a non-GAAP figure of $1.73. The primary adjustments adding back to the EPS were stock-based compensation ($0.78) and amortization of acquired intangible assets ($0.19), partially offset by tax effects - GAAP EPS of **$0.71** was adjusted upwards by a net **$1.02** to arrive at a Non-GAAP EPS of **$1.73** for Q2 2025. The largest positive adjustment was for stock-based compensation, contributing **$0.78 per share**[20](index=20&type=chunk) [Reconciliation of Net Income to Adjusted EBITDA](index=12&type=section&id=RECONCILIATION%20OF%20GAAP%20NET%20INCOME%20TO%20ADJUSTED%20EBITDA) Akamai's Adjusted EBITDA for Q2 2025 was $444.4 million, representing an Adjusted EBITDA margin of 43%. This was derived from a GAAP net income of $103.6 million by adding back items including depreciation and amortization ($135.8 million), stock-based compensation ($112.8 million), and provision for income taxes ($48.3 million) Q2 2025 Net Income to Adjusted EBITDA Reconciliation (in thousands) | Metric | Amount | | :--- | :--- | | **Net Income (GAAP)** | $103,618 | | **Adjustments (Taxes, Interest, D&A, Stock Comp, etc.)** | +$340,762 | | **Adjusted EBITDA** | $444,380 | | **Adjusted EBITDA Margin** | 43% | [Non-GAAP Financial Measures and Forward-Looking Statements](index=13&type=section&id=Non-GAAP%20Financial%20Measures%20and%20Forward-Looking%20Statements) This section explains the company's use of non-GAAP financial measures and provides a safe harbor statement regarding forward-looking information [Use and Definition of Non-GAAP Financial Measures](index=13&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) Akamai utilizes non-GAAP financial measures to supplement its GAAP results, believing they provide a better understanding of ongoing business performance and facilitate comparisons across periods. These measures exclude items that may be infrequent or not reflective of core operations - Management uses non-GAAP measures for operational decision-making, planning, and evaluating financial performance[23](index=23&type=chunk) - Key adjustments to derive non-GAAP figures include excluding: - Amortization of acquired intangible assets - Stock-based compensation - Acquisition-related costs - Restructuring charges - Amortization of debt issuance costs[26](index=26&type=chunk)[36](index=36&type=chunk) [Safe Harbor Statement](index=15&type=section&id=Akamai%20Statement%20Under%20the%20Private%20Securities%20Litigation%20Reform%20Act) This section serves as a safe harbor statement, cautioning that the press release contains forward-looking statements, including financial guidance, which are subject to various risks and uncertainties. It warns that actual results could differ materially from expectations due to factors like economic trends, competition, geopolitical events, and other risks detailed in SEC filings - The release contains forward-looking statements regarding future financial performance and prospects, which are not guarantees of future results[41](index=41&type=chunk) - Key risks that could impact results include macroeconomic trends, competition, geopolitical instability, supply chain issues, and the ability to integrate acquisitions[41](index=41&type=chunk) - Akamai disclaims any obligation to update these forward-looking statements in the future[42](index=42&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One): ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from __________ to __________ Commission File Number: 001-35975 Gogo Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35362 TRIPADVISOR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizatio ...

PRESS RELEASE August 7, 2025 Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results Conference Call and Webcast Today, August 7, 2025 at 4:30 p.m. ET PASADENA, Calif., August 7, 2025 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to achieve strong execution in discovery, clinical an ...